Research Article

Essential thrombocythemia: Biology, clinical features, thrombotic risk, therapeutic options and outcome

Vincenzo Accurso*, Santoro M, Contrino AD, Casimiro P, Raso S, Carlisi M, Sardo M, Perez A, Di Piazza F, Russo A and Siragusa S

Published: 09/02/2019 | Volume 3 - Issue 1 | Pages: 053-059


Essential Thrombocythemia (ET) is currently classified as a Philadelphia negative myeloproliferative neoplasm (MPN) together with polycythemia vera (PV) and primary myelofibrosis (PMF); the latter can be further divided in pre-fibrotic primary myelofibrosis (pre-PMF) and overt myelofibrosis, as listed in the revised 2016 World Health Organization classification of myeloid malignancies (WHO 2016). Overall, respect to the others MPNs, ET is characterized by favorable prognosis, lower life expectancy if compared to the control population, increased risk of thrombohemorrhagic complications along with possible evolution in myelofibrosis and leukemic transformation. In this review the authors will review current knowledge on biology, clinical aspects, prognosis and stratification of thrombotic risk, therapeutic options and outcome in ET patients.

Read Full Article HTML DOI: 10.29328/journal.jhcr.1001012 Cite this Article


  1. Daniel AA, Attilio Orazi, Robert Hasserjian, Thiele J, Borowitz MJ, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. BLOOD. 2016; 127: 20. PubMed:
  2. Ma X, Vanasse G, Cartmel B, Wang Y, Selinger HA. Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol. 2008; 83: 359-362. PubMed:
  3. Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006; 32: 171-173. PubMed:
  4. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990; 8: 556-562. PubMed:
  5. Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, et al. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990; 66: 549-556. PubMed:
  6. Tefferi A, Fonseca R, Pereira DL, Hoagland HC. A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc. 2001; 76: 22-28. PubMed:
  7. Tefferi A, Barbui T. Polycytemia vera and essential thrombocythemia: 2019 update on diagnosis, risk stratification and management. Am J Hematol. 2019; 94: 133-143. PubMed:
  8. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365: 1054-1061. PubMed:
  9. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia M with myelofibrosis. Cancer Cell. 2005; 7: 387-397.
  10. James C, Ugo V, Le Couedic J-P, Staerk J, Delhommeau F, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434: 1144-1148. PubMed:
  11. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, et al. A gain-offunctionmutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352: 1779-1790. PubMed:
  12. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, et al. Mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006; 108: 3472-3476. PubMed:
  13. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006; 3: e270. PubMed:
  14. Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin:the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood. 2014, 123: 3714-3719. PubMed:
  15. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013; 369: 2379-2392.
  16. Marty C, Pecquet C, Nivarthi H, El-Khoury M1, Chachoua I, et al. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood. 2016; 127: 1317-1324. PubMed:
  17. Mansier O, Luque Paz D, Ianotto JC, Le Bris Y, Chauveau A, et al. Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study. Am J Hematol. 2018; 93: 84-86. PubMed:
  18. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005; 366: 1945-1953. PubMed:
  19. Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C. The presence of the JAK2 mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol. 2006; 132: 244-245. PubMed:
  20. Zhang S, Qiu H, Fischer BS. JAK2 V617F patients with essential thrombocythemia present with clinical features of polycythemia vera. Leuk Lymphoma. 2008; 49: 696-699. PubMed:
  21. Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, et al. CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014; 123: 1544-1551. PubMed:
  22. Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014; 123: 1552-1555. PubMed:
  23. Pietra D, Rumi E, Ferretti VV, Di Buduo CA, Milanesi C, et al. Differential clinical effects of different mutation subtypes in CALR mutant myeloproliferative neoplasms. Leukemia. 2016; 30: 431-438. PubMed:
  24. Cabagnols X, Favale F, Pasquier F, Messaoudi K, Defour JP, et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood. 2016; 127: 333-342. PubMed:
  25. Milosevic Feenstra JD, Nivarthi H, Gisslinger H, Leroy E, Rumi E, et al. Sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood. 2016; 127: 325-332. PubMed:
  26. Yamamoto Y, Iba S, Abe A, et al. Elongation of MPL transmembrane domain is a novel activating-mutation in essential thrombocythemia. Blood. 2015; 126: 1628-1628.
  27. Tefferi A. Novel mutations and their functional andclinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010; 24: 1128-1138. PubMed:
  28. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369: 2391-2405. PubMed:
  29. Tefferi A, Lasho TL, Finke C. Targeted next-generation sequencing in polycythemia vera and essential thrombocythemia. Blood. 2015; 126: 354-354.
  30. Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients. Blood. 2011; 118: 2. PubMed:
  31. Andriani A, Latagliata R, Anaclerico B, Spadea A, Rago A, et al. Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients. American Journal of Hematology. 2016; 91: 3. PubMed:
  32. Dentali F, Ageno W, Rumi E, Casetti I, Poli D, et al. Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases. Thromb Res. 2014; 134: 41-43. PubMed:
  33. Chait Y, Condat B, Cazals-Hatem D, Rufat P, Atmani S, et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol. 2005; 129: 553-560. PubMed:
  34. Rumi E, Cazzola M. How I treat essential thrombocythemia. Blood. 2016; 128: 2403-2414. PubMed:
  35. Dentali F, Squizzato A, Brivio L, Appio L, Campiotti L, et al. JAK2V617F mutation for the early diagnosis of Ph myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood. 2009; 113: 5617-5623. PubMed:
  36. Roques M, Park JH, Minello A, Bastie JN, Girodon F. Detection of the CALR mutation in the diagnosis of splanchnic vein thrombosis. Br J Haematol. 2015; 169: 601-603. PubMed:
  37. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, et al. Philadelphia – Negative classical myeloproliferative neoplasms: critical concepts and management recomandation from European LeukemiaNet. J Clin Oncol. 2011; 29: 761-770. PubMed:
  38. Barbui T, Finazzi G, Carobbio A, et al. Development and validation an international Prognostic Score of thrombosis in World Health Organization essential thrombo cythemia. Blood. 2012; 120: 5128-5133. PubMed:
  39. Haider M, Gangat N, Lasho T, Abou Hussein AK, Elala YC, et al. Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients. Am J Hematol. 2016; 91: 4. PubMed:
  40. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2017 update, risk stratification, and management. Am J Hematol. 2017; 92: 94. PubMed:
  41. Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia. 2012; 26: 716-719. PubMed:
  42. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005; 128: 275-290. PubMed:
  43. Budde U, van Genderen PJ. Acquired von Willebrand disease in patients with high platelet counts. Semin Thromb Hemost. 1997; 23: 425-431. PubMed:
  44. Federici AB, Rand JH, Bucciarelli P, Budde U, Van Genderen PJ, et al. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost. 2000; 84: 345-349. PubMed:
  45. Passamonti F, Rumi E, Arcaini L, Boveri E, Elena C, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008; 93: 1645-1651. PubMed:
  46. Gangat N, Wolanskyj AP, McClure RF, Li CY, Schwager S, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia. 2006; 21: 270-276. PubMed:
  47. Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011; 29: 3179-3184. PubMed:
  48. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006; 81: 159-166. PubMed:
  49. Abdulkarim K, Ridell B, Johansson P, Kutti J, Safai-Kutti S, et al. The impact of peripheral blood values and bone marrowfindings on prognosis for patients with essential thrombocythemia and polycythemia vera. Eur J Haematol. 2011; 86: 148-155. PubMed:
  50. Pietra D, Rumi E, Ferretti VV, Di Buduo CA, Milanesi C, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia. 2016; 30: 431-438. PubMed:
  51. Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, et al, Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018; 32: 1057-1069. PubMed:
  52. Alvarez-Larran A, Pereira A, Guglielmelli P, Hernández-Boluda JC, Arellano-Rodrigo E, et al. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with CALR mutation. Haematologica. 2016; 101: 926-931. PubMed:
  53. Barbui T, De Stefano V. Addressing and proposing solutions for unmet clinical needs in the managementof myeloproliferative neoplasm-as-associated thrombosis: A consensus-based position paper. Blood Cancer Journal. 2019; 9: 61.
  54. Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, Spitzer G, Odenike O, et al. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. N Engl J Med. 2015; 373: 920-928. PubMed:
  55. Rambaldi A, Dellacasa CM, Finazzi G, Carobbio A, Ferrari ML, et al. A pilot study of the histonedeacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol. 2010; 150: 446-455. PubMed:
  56. Andersen CL, McMullin MF, Ejerblad E, Zweegman S, Harrison C, et al. A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2013; 162: 498-508. PubMed:
  57. Verstovsek S, Passamonti F, Rambaldi A, Barosi G5, Rumi E, et al. Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood. 2017; 130: 1768-1771. PubMed:
  58. Mora B, Passamonti F. Developments in diagnosis and treatment of essential thrombocythemia. Expert Review of Hematology. 2019; 12: 159-171. PubMed:
  59. Wright CA, Tefferi A. A single institutional experience with 43 pregnancies in essential thrombocythemia. Eur J Haematol. 2001; 66: 152-159. PubMed:
  60. Lavi N, Brenner B, Avivi I. Management of pregnant women with myeloproliferative neoplasms. Thromb Res. 2013; 131: S11-S13. PubMed:
  61. Passamonti F, Randi ML, Rumi E, Pungolino E, Elena C, et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617VF) mutation. Blood. 2007; 110: 485-489. PubMed:
  62. Randi ML, Bertozzi I, Rumi E, Elena C, Finazzi G, et al. Pregnancy complications predict thrombotic events in young women with essential thrombocythemia. Am J Hematol. 2014; 89: 306-309. PubMed:
  63. Alimam S, Bewley S, Chappell LC, Knight M, Seed P, et al. Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study. Br J Haematol. 2016; 175: 31-36. PubMed:
  64. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, et al. Philadelphia negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European leukemianet. J Clin Oncol. 2011; 29: 761-770. PubMed:
  65. Kreher S, Ochsenreither S, Trappe RU. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO),the Austrian Socie-ty of Hematology and Oncology (€OGHO) and Society of Thrombosis and Haemostasis Research (GTH eV). Ann Hematol. 2014; 93: 1953-1963.
  66. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004; 117: 755-761. PubMed:
  67. Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, et al. A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012; 120: 1197-1201. PubMed:
  68. Napolitano M, Siragusa S. Comparison of clinical and laboratory data, including JAK-2 46/1 haplotipe, between patients With Idiopathic Erythrocytosis and Polycythemia Vera. EHA22 Abstract book PB 2039.
  69. Hinds DA, Barnholt KE, Mesa RA, Kiefer AK, Do CB, et al. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. Blood. 2016; 128: 1121-1128. PubMed:
  70. Rumi E, Passamonti F, Pietra D, Della Porta MG, Arcaini L, et al. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer. 2000; 107: 2206–2211. PubMed:
  71. Bellanne-Chantelot C, Chaumarel I, Labopin M, Labopin M, Bellanger F, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood. 2006; 108: 346-352.
  72. Maffioli M, Mora B. Familial myeloproliferative neoplasms. A single institution: analysis of 22 families. EHA23 Abstract Book PS 1361.
  73. Rumi E, Cazzola M. How we treat essential thrombocythemia. Blood. 2016; 128: 2403-2414. PubMed: